Empower's new wellness clinic in Vancouver will support development of its psychedelics division.
Numinus Wellness Inc. has assembled the licensing and personnel to be a significant player in psilocybin-based drug research.
PharmaDrug adds depth to its board with new Director who has a wealth of healthcare and addiction-therapy experience.
Champignon Brands closes on a $15 million financing to expand its clinical psychedelics research programs.
Numinus becomes the first publicly traded company in Canada to obtain such licensing for psychedelics research.
As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.